^
    2d
    SWOG-S0518: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (clinicaltrials.gov)
    P3, N=427, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    Avastin (bevacizumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Mycapssa (octreotide) • Avzivi (bevacizumab-tnjn) • Intron A (interferon α-2b) • Bioferon (interferon alpha 2b) • octreotide acetate
    1m
    Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas (clinicaltrials.gov)
    P2, N=2, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.
    Trial termination
    |
    BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
    |
    BRCA mutation
    |
    Trodelvy (sacituzumab govitecan-hziy) • Mycapssa (octreotide) • loperamide • octreotide acetate solution for injection